Antipsychotic drug Abilify®
Aripiprazole, also known by its brand name Abilify® is an atypical antipsychotic drug. Abilify® can treat psychotic conditions like depression, schizophrenia, bipolar disorder, Tourette syndrome and others. It can also be prescribed to treat irritability associated with autism.
Aripiprazole was developed by Otsuka Pharmaceutical Co., Ltd. in Japan. In the United States, Otsuka America markets Abilify® jointly with Bristol-Myers Squibb. According to IMS Health, sales of Abilify® were more than $9 billion during 2014.
Schizophrenia is a relatively rare condition, and numbers of prescriptions for Abilify® were not significant for manufacturers. Otsuka and Bristol-Myers applied for FDA approval to use Abilify® for more conditions. Once the FDA approved other uses of Abilify®, the drug became a profitable resource for manufacturers.
In combination with other drugs, Abilify® is marketed today as an atypical antipsychotic drug for treating major depressions, bipolar disorder, and irritability associated with autism.
Abilify® is a registered trademark of Bristol-Myers Squibb and Otsuka America Pharmaceutical